Application of Disitamab Vedotin in the Multiline Treatment of EGFR Mutation-positive Lung Adenocarcinoma with Her-2 Overexpression

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Dec 27

PMID 39726714

Authors

Meiling Lan

Tianyun Wang

Diexiao Luo

Yan Chen

Wei Liang

Rui Kong

Qichao Xie

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the efficacy of c in the multiline treatment of late-stage lung adenocarcinoma with Her-2 overexpression and epidermal growth factor receptor (EGFR) mutations.

Methods: We summarize the diagnosis and treatment of a female patient with EGFR 21L858R mutation combined with Her-2 overexpression in advanced lung adenocarcinoma, and analyze the effect of c in her treatment process.

Results: The patient was diagnosed with lung adenocarcinoma 8 years ago. After first-line treatment, the lung lesions enlarged. Following second-line treatment 5 years ago, intracranial metastasis occurred. After third-line treatment 3 years ago, intracranial and lung lesions enlarged. New lesions in the lungs, liver, and spleen appeared after fourth-line treatment 32 months ago. Lung progression occurred after fifth-line treatment 29 months ago. Liver and lung progression occurred after sixth-line treatment 22 months ago. Lung progression occurred after seventh-line treatment 19 months ago. The patient underwent eighth-line treatment with disitamab vedotin (RC48) + lung radiotherapy + liver intervention 13 months ago. Currently, the patient's condition is stable, with a good quality of life, and the efficacy assessment is stable disease (SD). Conclusion: Her-2 overexpression can occur in late-stage EGFR-mutant lung adenocarcinoma after multiline treatment. RC48 can achieve sustained remission in these patients.

References

Tsurutani J, Iwata H, Krop I, Janne P, Doi T, Takahashi S . Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discov. 2020; 10(5):688-701. PMC: 8292921. DOI: 10.1158/2159-8290.CD-19-1014. View

Reck M, Mok T, Nishio M, Jotte R, Cappuzzo F, Orlandi F . Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019; 7(5):387-401. DOI: 10.1016/S2213-2600(19)30084-0. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Smit E, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodriguez L . Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet Oncol. 2024; 25(4):439-454. DOI: 10.1016/S1470-2045(24)00064-0. View

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Bharat A . Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(5):497-530. DOI: 10.6004/jnccn.2022.0025. View

Song Z, Lv D, Chen S, Huang J, Li Y, Ying S . Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial. Clin Cancer Res. 2021; 28(3):461-467. DOI: 10.1158/1078-0432.CCR-21-2936. View

Li B, Shen R, Buonocore D, Olah Z, Ni A, Ginsberg M . Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. J Clin Oncol. 2018; 36(24):2532-2537. PMC: 6366814. DOI: 10.1200/JCO.2018.77.9777. View

Wang P, Xia L . RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study. BMC Cancer. 2023; 23(1):1083. PMC: 10636982. DOI: 10.1186/s12885-023-11593-9. View

10.

Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H . Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2020; 27(1):43-51. DOI: 10.1158/1078-0432.CCR-20-2488. View

11.

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

12.

Garassino M, Cho B, Kim J, Mazieres J, Vansteenkiste J, Lena H . Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018; 19(4):521-536. PMC: 7771363. DOI: 10.1016/S1470-2045(18)30144-X. View

13.

Herbst R, Morgensztern D, Boshoff C . The biology and management of non-small cell lung cancer. Nature. 2018; 553(7689):446-454. DOI: 10.1038/nature25183. View

14.

Li B, Smit E, Goto Y, Nakagawa K, Udagawa H, Mazieres J . Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2021; 386(3):241-251. PMC: 9066448. DOI: 10.1056/NEJMoa2112431. View

15.

Peng Z, Liu T, Wei J, Wang A, He Y, Yang L . Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond). 2021; 41(11):1173-1182. PMC: 8626607. DOI: 10.1002/cac2.12214. View

16.

Zhang X, Zeng L, Li Y, Xu Q, Yang H, Lizaso A . Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China. Cancer Immunol Immunother. 2021; 70(9):2517-2528. PMC: 10991983. DOI: 10.1007/s00262-021-02869-9. View

17.

Riudavets M, Sullivan I, Abdayem P, Planchard D . Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open. 2021; 6(5):100260. PMC: 8414039. DOI: 10.1016/j.esmoop.2021.100260. View

18.

Yang C, Yang J, Yang P . Precision Management of Advanced Non-Small Cell Lung Cancer. Annu Rev Med. 2020; 71:117-136. DOI: 10.1146/annurev-med-051718-013524. View

19.

Jiang T, Wang P, Zhang J, Zhao Y, Zhou J, Fan Y . Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial. Signal Transduct Target Ther. 2021; 6(1):355. PMC: 8517012. DOI: 10.1038/s41392-021-00751-9. View

20.

Mar N, Vredenburgh J, Wasser J . Targeting HER2 in the treatment of non-small cell lung cancer. Lung Cancer. 2015; 87(3):220-5. DOI: 10.1016/j.lungcan.2014.12.018. View